HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Annora Pharma Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Annora Pharma Intelligence Report

Generated from 2 signals · 3 evidence sources

Type

Company Intelligence Report

Generated

Jun 24, 2026

Confidence

Moderate Confidence · 70%

Evidence

12 items

Sources

10

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Annora Pharma maintains an active intelligence profile across Allergy, Antihistamine, Hematology, Spleen Tyrosine Kinase Inhibitor. 2 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 70% across 3 tracked sources. Highest-priority development: FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL). Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Annora Pharma; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    FDA AP — MEPERIDINE HYDROCHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    Phase 1 Investigational New Drug (IND) Navigator

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    Ongoing | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    Clinical trials for medicines: modifying a clinical trial approval

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    Withdrawn | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    Oncology (Cancer)/Hematologic Malignancies Approval Notifications

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 43 with buyer quality 7 (Emerging). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MEPERIDINE HYDROCHLORIDE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Phase 1 Investigational New Drug (IND) Navigator

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Ongoing | Cancer Accelerated Approvals

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Clinical trials for medicines: modifying a clinical trial approval

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • Withdrawn | Cancer Accelerated Approvals

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Oncology (Cancer)/Hematologic Malignancies Approval Notifications

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Grants Approval for Fostamatinib Disodium ANDA217329

    Hematology · Spleen Tyrosine Kinase Inhibitor

  • FDA Grants Approval for Diphenhydramine Hydrochloride ANDA219470

    Allergy · Antihistamine

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.